News about Global Pharma

Geneseeq's CanScan Earns FDA Breakthrough Designation for Advanced Cancer Detection

This cutting-edge technology utilizes low-depth whole-genome sequencing on circulating cell-free DNA, demonstrating an impressive 99 percent specificity in identifying early cancer signals.

Global Pharma | 05/01/2024 | By Manvi |  1029

Lupin Gets Tentative Approval from U.S. FDA for Dapagliflozin and Saxagliptin Tablets

Dapagliflozin and Saxagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Global Pharma | 05/01/2024 | By Manvi |  605

Immunexpress Receives FDA Clearance for EDTA Blood-Compatible Cartridges for SeptiCyte RAPID

The inclusion of undiluted EDTA blood as a validated sample type is expected to enhance the utility of SeptiCyte RAPID® in the US clinical setting.

Global Pharma | 05/01/2024 | By Manvi |  665

WuXi XDC Enters into Partnership Agreement with IntoCell

Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel Camptothecin drugs called NexatecansTM, a new class of OHPAS-able Camptothecins.

Global Pharma | 04/01/2024 | By Manvi |  868

MediLink Therapeutics and Roche Announces Worldwide Collaboration and License Agreement

MediLink Therapeutics have announced that it has entered into a worldwide collaboration and license agreement with Roche on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumours.

Global Pharma | 04/01/2024 | By Manvi |  276

Glenmark is First to Launch Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India

Glenmark Pharmaceuticals Ltd. has launched a biosimilar of the popular10,11 anti?diabetic drug, Liraglutide, for the first time in India.

Global Pharma | 04/01/2024 | By Manvi |  691

Renovos Biologics Awarded FDA Breakthrough Device Designation for RENOVITE BMP-2

The breakthrough designation is a recognition of RENOVITE® BMP-2's potential to provide more effective diagnosis and treatment for conditions related to bone regeneration.

Global Pharma | 04/01/2024 | By Manvi |  649

Boehringer Ingelheim and Ribo Collaborate to Pave Way for Innovative Liver Disease Treatments

With over 440 million people worldwide estimated to live with NASH, an inflammatory liver disease triggered by fat accumulation, the collaboration addresses a pressing need for effective treatment options.

Global Pharma | 03/01/2024 | By Manvi |  663

AnX Robotica Receives FDA Clearance for NaviCam ProScan

The ProScan software, an artificial intelligence (AI) assisted reading tool, utilizes cutting-edge technology to reshape the landscape of gastroenterology.

Global Pharma | 03/01/2024 | By Manvi |  1265

Verona Pharma Enters into Debt Facility of Up to USD 400 Mn with Oxford Finance and Hercules Capital

Verona Pharma plc, announces it and its wholly-owned subsidiary, Verona Pharma, Inc., have entered into a debt financing facility providing the Company with access to up to USD 400 million from funds managed by Oxford Finance LLC and Hercules Capital, Inc.

Global Pharma | 03/01/2024 | By Manvi |  647